Gastrointestinal Stromal Tumor: A Clinical Overview

Hematology/Oncology Clinics of North America

Volumn 23, Issue 1, 2009, Pages 69-78

  Quek, Richard ^a,b   George, Suzanne ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Gastrointestinal stromal tumors; GIST; Imatinib; Review; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB; SUNITINIB;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INHIBITION; DRUG TOLERABILITY; EDEMA; FAMILIAL DISEASE; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HISTORY OF MEDICINE; HUMAN; MOLECULAR BIOLOGY; NAUSEA; PRIORITY JOURNAL; RARE DISEASE; RASH; REVIEW; RISK ASSESSMENT; SKIN DISCOLORATION; TUMOR LOCALIZATION;

DIGESTIVE SYSTEM SURGICAL PROCEDURES; FAMILY HEALTH; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 60549100690     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.11.006     Document Type: Review

References (55)

1. Stout A.P. Bizarre smooth muscle tumors of the stomach. Cancer 15 (1962) 400
2. Somerhausen Nde S., and Fletcher C.D. Gastrointestinal stromal tumours: an update. Sarcoma 2 3-4 (1998) 133-141
3. Welsh R.A., and Meyer A.T. Ultrastructure of gastric leiomyoma. Arch Pathol 87 1 (1969) 71-81
4. Weiss R.A., and Mackay B. Malignant smooth muscle tumors of the gastrointestinal tract: an ultrastructural study of 20 cases. Ultrastruct Pathol 2 3 (1981) 231-240
5. Yagihashi S., Kimura M., Kurotaki H., et al. Gastric submucosal tumours of neurogenic origin with neuroaxonal and Schwann cell elements. J Pathol 153 1 (1987) 41-50
6. Mazur M.T., and Clark H.B. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 7 6 (1983) 507-519
7. Herrera G.A., Cerezo L., Jones J.E., et al. Gastrointestinal autonomic nerve tumors. 'Plexosarcomas'. Arch Pathol Lab Med 113 8 (1989) 846-853
8. Lauwers G.Y., Erlandson R.A., Casper E.S., et al. Gastrointestinal autonomic nerve tumors. A clinicopathological, immunohistochemical, and ultrastructural study of 12 cases. Am J Surg Pathol 17 9 (1993) 887-897
9. Mikhael A.I., Bacchi C.E., Zarbo R.J., et al. CD34 expression in stromal tumors of the gastrointestinal tract. Appl Immunohistochem 2 (1994) 89-93
10. Miettinen M., Virolainen M., and Sarlomo-Rikala M. Gastrointestinal stromal tumors- value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 19 2 (1995) 207-216
11. Nagata H., Worobec A.S., Oh C.K., et al. Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92 23 (1995) 10560-10564
12. Longley B.J., Tyrrell L., Lu S.Z., et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 12 3 (1996) 312-314
13. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 5350 (1998) 577-580
14. Kindblom L.G., Remotti H.E., Aldenborg F., et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152 5 (1998) 1259-1269
15. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 14 (2001) 1052-1056
16. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 7 (2002) 472-480
17. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 9544 (2006) 1329-1338
18. DeMatteo R.P., Lewis J.J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231 1 (2000) 51-58
19. Joensuu H., Fletcher C., Dimitrijevic S., et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3 11 (2002) 655-664
20. Nilsson B., Bümming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era- a population-based study in western Sweden. Cancer 103 4 (2005) 821-829
21. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33 5 (2002) 459-465
22. Rudolph P., Gloeckner K., Parwaresch R., et al. Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathologic study. Hum Pathol 29 8 (1998) 791-800
23. Emory T.S., Sobin L.H., Lukes L., et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 23 1 (1999) 82-87
24. Miettinen M., and Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23 2 (2006) 70-83
25. Demetri G.D., Benjamin R.S., Blanke C.D., et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)- update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5 Suppl 2 (2007) S1-S29
26. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 23 (2003) 4342-4349
27. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol 22 18 (2004) 3813-3825
28. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42 8 (2006) 1093-1103
29. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 5607 (2003) 708-710
30. Corless C.L., McGreevey L., Haley A., et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160 5 (2002) 1567-1572
31. Heinrich M.C., Rubin B.P., Longley B.J., et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33 5 (2002) 484-495
32. Janeway K.A., Liegl B., Harlow A., et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 67 19 (2007) 9084-9088
33. Agaram N.P., Laquaglia M.P., Ustun B., et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 14 10 (2008) 3204-3215
34. Tarn C., Rink L., Merkel E., et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 105 24 (2008) 8387-8392
35. Kleinbaum E.P., Lazar A.J., Tamborini E., et al. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. Int J Cancer 122 3 (2008) 711-718
36. Li F.P., Fletcher J.A., Heinrich M.C., et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 23 12 (2005) 2735-2743
37. Chompret A., Kannengiesser C., Barrois M., et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 126 1 (2004) 318-321
38. Carney J.A. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 74 6 (1999) 543-552
39. Zöller M.E., Rembeck B., Odén A., et al. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 79 11 (1997) 2125-2131
40. Miettinen M., Fetsch J.F., Sobin L.H., et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 30 1 (2006) 90-96
41. Blay J.Y., Bonvalot S., Casali P., et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 16 4 (2005) 566-578
42. DeMatteo RP, Owzar K, Antonescu CR, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000. J Clin Oncol 2005;23(16S):9009.
43. DeMatteo RP, Owzar K, Maki R, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. 2005 American Society of Clinical Oncology Annual Meeting Proceedings, Orlando, FL, May 13-17, 2005.
44. Edmonson J.H., Marks R.S., Buckner J.C., et al. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 20 5-6 (2002) 605-612
45. Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26 4 (2008) 620-625
46. Van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 9291 (2001) 1421-1423
47. Blanke C.D., Rankin C., Demetri G.D., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26 4 (2008) 626-632
48. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 9440 (2004) 1127-1134
49. Van Glabbeke MM, Owzar K, Rankin C, et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analyis based on 1,640 patients (pts). J Clin Oncol 2007;25(18S):10004.
50. Van den Abbeele A, Melenevsky Y, de Vries D, et al. Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST). J Clin Oncol 2005;23(16S):9006.
51. George S., Blay J.Y., Casali P.G., et al. Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: updated efficacy, safety, PK and pharmacodynamic analysis. J Clin Oncol 26 (2008) [May 20 suppl; abstr 10554]
52. Desai J., Yassa L., Marqusee E., et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145 9 (2006) 660-664
53. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370 9604 (2007) 2011-2019
54. Wiebe L., Kasza K.E., Maki R.G., et al. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol 26 (2008) [May 20 suppl; abstr 10502]
55. Wagner A.J., Morgan J.A., Chugh R., et al. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from phase I trial. J Clin Oncol 26 (2008) [May 20 suppl; abstr 10502]